### **INVESTMENT OBJECTIVE**

To achieve capital appreciation on an absolute and relative basis over the medium to long-term horizon through investment in Swiss equities with a focus on innovative companies that are leaders in their markets profile.

### **PORTFOLIO REVIEW**

Swiss equities posted their fifth consecutive month of gains in March, with a 3.9% rebound that lifted them to their highest level since April 2022. The SPI index is now just 6% shy of its December 2021 all-time record. The good news of the month was the Swiss National Bank's (SNB) surprise decision to cut interest rates by a quarter of a point, becoming the first major central bank to pave the way for a less restrictive monetary policy. By weakening the Swiss franc, the SNB has given Swiss exporters some welcome breathing space, particularly for the smallest companies that cannot always offset the effects of a strong franc by relocating production. If this trend continues, the positive impact on corporate profits could be significant in the second half of the year.

The Bruellan Dynamic Swiss fund posted a 4.1% gain, bringing its quarterly performance to

While the vast majority of stocks in our selection rose during the month under review, the largest increases were booked by Lonza (+17%) and Accelleron (+13%), for the second month running, as well as Givaudan (+10%) and Flughafen Zurich (+10%).

Lonza once again posted a significant monthly gain, putting it at the top of the year-to-date SMI performance table (+53%). Since the October lows, its performance even exceeds 70%. After a number of setbacks last year, including several profit warnings and the surprise departure of the CEO, the recent confirmation of medium-term guidance and the appointment of a new Chairman of the Board and then a new CEO have restored investor confidence in a company operating in a sector that remains very buoyant, with strong structural growth.

The only stocks not to have posted a positive performance in March were Swiss Life (-1%). Sandoz (-1%) and Alcon (-1%).

### **RISK & REWARD**

1	2	3	4	5	6	7
Low						High

### ELIND EACTS

FUND FACTS	
Domicile	Luxembourg (UCITS)
Inception date	10 June 2021
Currency	CHF
Lead Manager	Anick Baud
Co-Manager	Florian Marini CFA, CMT
Fund size*	CHF 27 Millions
Liquidity (sub./red.)	Daily
Min. Investment	Instit.: 1 million CHF
Entry/exit fees	0.0% / 0.0%
Management fees	0.8%
Performance fees	20%
High Water Mark	Yes

MSCI Switzerland 10-40 Benchmark ISIN Instit.: LU2264701074

Instit.: PRPSEIC LX Bloomberg


NAV Instit: 95.33

**STATISTICS** 

Not all the costs are presented, further information can be found in the prospectus or equivalent

		MSCI Switzerland
	Fund	10-40
Leading PE	20.1	15.1
EV/EBITDA	18.9	12.4
P/Book	4.7	1.7
Dividend Yield	2.3%	2.6%
ROE	21.0%	9.8%
Debt/Equity	54.3%	57.7%
Interest Coverage	17.6	8.2
Beta	1.2	1.0
Volatility	17.3%	13.5%

### **ALLOCATION BY MARKET CAP**



### **NET PERFORMANCE AND ANNUAL PERFORMANCE IN CHF**



	MSCI		
	Fund	Switzerland 10-40	+/-
1 Month	3.8%	4.1%	-0.3%
3 Months	4.9%	7.5%	-2.7%
YTD	4.9%	7.5%	-2.7%
Since inception	-4.7%	4.2%	-8.8%

Source: All data and graphs throughout the document from Bruellan

Past performance may not be a reliable guide to future performance. All forms of investment involve risk.

The benchmark index is the MSCI Switzerland 10-40.

Please refer to the end of the document mentioned for performance comparison purposes.


<sup>\*</sup> the total strategy size is CHF 55 millions

# BAM SWISS EQUITIES

# MARCH 2024



# **ALLOCATION BY SECTOR**



■ Portfolio ■ Benchmark

# **FUND COMPLEMENTARY DETAILS**

Administrator Representative in Switzerland Investment Manager Paying agent in Switzerland Auditor Custodian

FundPartner Solutions (Suisse) SA Bruellan SA Banque Pictet & Cie SA

Fund Partner Solutions SA

Deloitte Audit SARL Bank Pictet & Cie (Europe) AG, Succursale de Luxembourg

### **TOP 10 HOLDINGS**

	Sector	Weight
NESTLE SA-REG	Consumer Staples	8.6%
NOVARTIS AG-REG	Health Care	8.1%
ROCHE HOLDING AG-GENUSSCHEIN	Health Care	6.4%
STRAUMANN HOLDING AG-REG	Health Care	4.4%
ZURICH INSURANCE GROUP AG	Financials	4.2%
LONZA GROUP AG-REG	Health Care	4.0%
SIKA AG-REG	Materials	4.0%
CIE FINANCIERE RICHEMO-A REG	Consumer Discretionary	3.8%
ACCELLERON INDUSTRIES AG	Industrials	3.8%
FISCHER (GEORG)-REG	Industrials	3.7%
Total		51.1%

Total number of Holdings

# **CONTACT**

BRUELLAN SA Rue Pécolat 1 CH-1201 Genève Tél: +41 22 817 18 55 bam@bruellan.ch

Disclaimer. Bruellan SA has a FINMA authorisation as a collective asset manager. This publication is a promotional document within the meaning of art. 68 LSFin, it is not independent research. It is solely intended to provide information on the funds in question and does not constitute an offer to buy or sell, investment advice or a recommendation regarding investment or other decisions. The funds may be subject to sales restrictions applicable to certain countries or individuals. It is the responsibility of each investor to be aware of the terms and conditions applicable to each product. This publication is directed only at persons authorised to receive it under the regulations in force in their country of domicile.

2.7

The information contained herein is based on sources believed to be reliable. This is a marketing communication. Bruellan cannot guarantee its completeness and accuracy and accepts no liability for any damage that may result from actions taken on the basis of the information published in this document. The information reflects the situation on the day of publication. We have classified this product as 5 out of 7, which is a medium - high risk class. Please refer to the prospectus for more information on the specific risks relevant to this product not included in the summary indicator.

Investment decisions should always be made on the basis of a detailed source of information, in particular the fund prospectus. The prospectus, the articles of association, the key information document, the subscription form and the latest annual and semi-annual reports can be obtained (free of charge) from the Swiss representative, Fund Partner Solutions (Suisse) SA, 60, route des Acacias, 1211 Geneva. Please refer to the prospectus and information document of the fund before making any final investment decisions. You can obtain a summary of investors rights to the following link: https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-investors-rights.pdf. The decision to invest in the promoted fund should take into account all the

characteristics or objectives of the promoted fund as described in its prospectus. Information on sustainability-related aspects provided in relation to the promoted fund could be found on the following link: https://assetservices.group.pictet/asset-services/esg-disclosures?isin=LU118008553. Incorporation of extra-financial risks into the investment decision process may result in underweighting of profitable investments from the sub-fund's investment universe and may also lead the management of the sub-fund to underweight investments that will continue to perform. The Fund has been classified as a financial product subject to Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial sector (the "SFDR"). The Fund promotes, among other characteristics, environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices. Performance disclosures: the published performance represents past data. Past performance may not be a reliable guide to future performance. There is no guarantee that the same yields will be obtained in the future. The value and income of any of your investments may fluctuate with market conditions and may lose some or all its value. The fund may be affected by changes in currency exchange rates, which can have an adverse effect on the value or income of the fund. Future performance is also subject to taxation which depends on the personal situation of each investor and which may change in the future. All performance data are based on net performance and take no account of commissions, fees or other costs charged when units are issued and redeemed.